Athenahealth sale ‘possible’ with activist investor taking 9.2% stake

John Gregory | | Health Exec | Economics

Activist hedge fund manager Paul Singer of Elliott Management disclosed its 9.2 percent stake in Watertown, Massachusetts-based Athenahealth, sending the company’s stock price soaring.

While Elliott’s federal filing said it feels Athena is “significant undervalued,” according to Boston Business Journal, the ultimate goal may be to cost cuts or force a sale of the health IT company, as it has done in the past.

“While a sale of the company is possible, we note Elliott has pursued other paths to value in the past, and we believe the fund may push for a cost reduction program, given Athena’s revenue slow-down and high operating costs,” Leerink analysts said in a report.

Read the full article at the link below: 

Sale or cost cuts at athenahealth 'possible' with new activist investor, says a…

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.